Effect of nanocurcumin on serum levels of betatrophin and irisin in patients with metabolic syndrome; a clinical trial

Abstract

Introduction: Metabolic syndrome is a highly prevalent disease with combination of cardio metabolic risk factors. Insulin resistance is the most important reason of metabolic syndrome. Objectives: The study aimed to evaluate the effects of nanocurcumin on insulin resistance and serum level irisin and betatrophin in patients with metabolic syndrome. Patients and Methods: Sixty metabolic syndrome patients (30 males and 30 females) received 80 mg/daily nanocurcumin for three months. The samples of fasting blood were collected at the beginning of the study and after 90-days intervention to measure the biomarkers. Results: comparing pre and post treatment with nanocurcumin values revealed a significant change in fasting plasma glucose (FPG), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and irisin (P>0.05), but there was no change in the amount of betatrophin (P>0.05). Conclusion: According to the results, it seems that the use of nanocurcumin for 90 days may have positive effects on some metabolic components. However, more studies with larger sample sizes are needed to confirm the findings. Trial registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20120215009014N214; https:// www.irct.ir/trial/30187, ethical code; IR.UMSHA.REC.1396.859).